Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Title||Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)|
|Sponsors||Blueprint Medicines Corporation|
|Age Groups:||adult | senior|
|Covered Countries||USA | ITA | GBR | FRA | ESP | DEU | BEL|